Too Much Medicine

Attention-deficit/hyperactivity disorder: are we helping or harming?

BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f6172 (Published 5 November 2013)
Cite this as: BMJ 2013;347:f6172

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Rae Thomas, senior research fellow1,
  2. Geoffrey K Mitchell, professor of general practice and palliative care2,
  3. Laura Batstra, assistant professor3
  1. 1Centre for Research in Evidence-Based Practice, Bond University, 4229 Australia
  2. 2School of Medicine, University of Queensland, 4072 Australia
  3. 3Department of Special Needs Education and Youth Care, University of Groningen, Netherlands
  1. Correspondence to: R Thomas rthomas{at}bond.edu.au

Summary box

  • Clinical context—The prevalence of attention-deficit/hyperactivity disorder (ADHD) has increased substantially in the past decade, with most children diagnosed with ADHD described as having mild or moderate ADHD. Medication prescription rates have also increased twofold for children and fourfold for adolescents and adults

  • Diagnostic change—Definitions of ADHD have been broadened in successive editions of DSM

  • Rationale for changeConcern that ADHD is underdiagnosed in some children and adults

  • Leap of faith—Identifying and treating more people with ADHD will improve their quality of life

  • Impact on prevalence—The prevalence of parent reported diagnosis of ADHD in the US rose from 6.9% in 1997 to 9.5% in 2007. In the Netherlands it doubled over a similar period and other countries have also seen similar rises

  • Evidence of overdiagnosis—Severity of ADHD criteria is subjective. Prevalence varies markedly within and between countries and there is evidence that inappropriate developmental comparisons, sex, and heuristics contribute to inappropriate diagnoses

  • Harms from overdiagnosis—Medication costs of inappropriately diagnosed ADHD are estimated to be between $320m (£200m; €230m) and $500m in the US and some children have adverse drug reactions. While a diagnosis may help children and families it also carries stigma; children labelled as having ADHD are perceived as lazier and less clever by peers, and teachers and parents have low academic expectations of them potentially creating a self fulfilling prophecy

  • Limitations—Longitudinal data on the prognosis of ADHD and effects of treatments are limited

  • Conclusions—Reducing the threshold for diagnosing ADHD devalues the diagnosis in those with serious problems. A conservative stepped diagnostic approach could reduce the risk of overdiagnosis

Prevalence and prescribing rates for attention-deficit/hyperactivity disorder (ADHD) have risen steeply over the past decade, partly in response to concerns about underdiagnosis and undertreatment.1 2 But although clinicians have become better …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL